Invokana® Injury Lawsuits
Invokana® (canagliflozin) and Invokamet® (canagliflozin and metformin hydrochloride) are prescription medications for the treatment of Type 2 Diabetes. Invokana and Invokamet are manufactured and marketed by Janssen Pharmaceuticals and Johnson & Johnson, and were first approved by the FDA on March 29, 2013.
Despite the fact that Invokana and Invokamet have only been on the market for a short time, there has been a shockingly high number of adverse events reported in patients taking these drugs, including kidney failure, ketoacidosis, and myocardial infarction (heart attack). In fact, on May 6, 2015, the Institute for Safe Medication Practices published a Report regarding the distressing number of adverse events in which Invokana use led to kidney impairment. And on May 15, 2015, the FDA issued a Safety Announcement that linked Invokana and other sodium-glucose cotransporter-2 (SGLT2) inhibitors to ketoacidosis.
The most serious potential side effects caused by Invokana® are kidney failure, ketoacidosis, and myocardial infarction.
- Kidney Failure (also known as renal failure or renal insufficiency) occurs when the kidneys stop functioning correctly and do not properly filter waste products from the blood. Kidney failure is a serious medical condition that requires medical treatment, and can cause fatigue, confusion, weakness, muscle damage, and death.
- Ketoacidosis, which is normally associated with uncontrolled Type 1 Diabetes, occurs when the body cannot use glucose for energy and instead breaks down fat and proteins. As a result, dangerous levels of acid, known as ketones, build up in the body. Ketoacidosis is a serious, life-changing medical condition that requires intensive treatment and can result in organ failure, coma, or even death.
- Myocardial Infarction (also known as a heart attack) occurs when blood flow is restricted to the heart, thereby depriving it of oxygenated blood. When the heart is deprived of oxygen for too long, the heart tissue begins to die. A heart attack is a serious medical condition that can cause death and requires immediate medical attention.
Schlichter Bogard & Denton is aggressively investigating claims against the manufacturers of Invokana as it appears there was a failure to adequately research these new drugs before they were sold in the United States. In addition, patients and their doctors have not been properly warned about the risks of kidney failure, ketoacidosis, or heart attack associated with the use of the drugs.
Hundreds of Invokana lawsuits filed across the nation against the drug makers have been consolidated into a multidistrict litigation (MDL 2750) pending in the U.S. District Court for the District of New Jersey. Ashley Brittain-Landers of Schlichter Bogard & Denton has been appointed to the Plaintiffs’ Steering Committee, where she will co-lead this national litigation.
If you or someone you know has suffered kidney failure, ketoacidosis, or heart attack while using Invokana or Invokamet, you may be entitled to compensation. Contact Schlichter Bogard & Denton for a free case consultation.